Immatics reported promising initial anti-tumor activity for its second-generation PRAME cell therapy IMA203CD8 in a Phase 1a dose escalation trial, showing encouraging clinical responses across multiple cancer types, particularly in ovarian carcinoma.

Immatics N.V. plans to sell 12.5 million ordinary shares at $10.00 per share, expecting to raise $125 million in a public offering managed by Jefferies, Leerink Partners, and Cantor.

Immatics reported promising Phase 1a clinical trial results for two bispecific cancer therapies, IMA402 and IMA401, demonstrating favorable tolerability and deep, durable responses in heavily pre-treated patients with solid tumors across multiple cancer types.

Immatics N.V. announced the appointment of Venkat Ramanan, Ph.D. as its new Chief Financial Officer, replacing Arnd Christ. Dr. Ramanan brings over 25 years of biopharmaceutical finance experience from companies like Seagen, Gilead Sciences, and Amgen.

The T-cell receptor (TCR) therapy pipeline is rapidly expanding, with over 80 pharmaceutical companies actively developing more than 100 TCR therapies for various cancers, including solid tumors. Several promising pipeline candidates are in different stages of clinical trials, showcasing the potential of TCR therapy to revolutionize cancer treatment.

Immatics announced positive clinical data for its TCR-T therapy candidates targeting PRAME, a protein frequently expressed in solid cancers. The data showed deep and durable responses in heavily pretreated patients, supporting the advancement of these therapies into late-stage development.

Immatics, a clinical-stage biopharmaceutical company, announced the pricing of its $150 million public offering of 16,250,000 ordinary shares at $9.25 per share. The offering is expected to close on October 15, 2024.

Immatics, a clinical-stage biopharmaceutical company, announced upcoming oral and poster presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024. The presentations will focus on their TCR-T therapies targeting the PRAME antigen for the treatment of solid cancers.

Immatics reported positive clinical data for its ACTengine® IMA203 targeting PRAME in metastatic melanoma patients, with a 55% confirmed objective response rate and a favorable tolerability profile. The company also announced upcoming data presentations for its TCR Bispecifics pipeline, including IMA401 and IMA402, and the appointment of Alise Reicin, M.D. to its Board of Directors.

Memo Therapeutics AG, a late-stage biotech company, has appointed Paul Carter as its new Chairperson. Carter has extensive experience in the biopharma industry, particularly in the virology field, and will support the company's Phase III readiness and commercial preparations for its lead program, AntiBKV.

U.S. stocks closed higher on Tuesday as investors digested the key inflation data that heightened worries regarding inflation.

Immatics (IMTX) delivered earnings and revenue surprises of 94.59% and 85.05%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?